Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eagle Pharmaceuticals (EGRX) PT Raised to $84 at RBC Capital
August 8, 2018 8:32 AM EDTRBC Capital raised its price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $84.00 (from $74.00) while maintaining a Outperform rating.
... MoreEagle Pharmaceuticals (EGRX) Tops Q2 EPS by 15c, Revenues Beat
August 7, 2018 6:52 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.95, $0.15 better than the analyst estimate of $0.80. Revenue for the quarter came in at $59.3 million versus the consensus estimate of $51.23 million.
Total revenue for the second quarter of 2018 was $59.3 million, compared to $50.1 million in the second quarter of 2017;Eagle launched bendamustine hydrochloride 500ml solution (Big Bag) on May 15, 2018 and Big Bag product sales were $8.1 million in the second quarter of 2018;Q2 2018 Ryanodex product sales were $7.2 million, up 38% compared to Q2 2017;Q2 2018 net income was $2.7 million, or $0.18 per basic and $0.17 per diluted... More